EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische Studie

Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder

Maurizio Fava, Luca Pani, Sara De Martin, Andrew J Cutler, Charles W Gorodetzky, Frank J Vocci, Frank L Sapienza, Thomas R Kosten, Cornelia Kröger, Paggard Champasa, Clotilde Guidetti, Stefano Comai und 7 weitere

The Journal of Clinical Psychiatry · 2025

DOI: 10.4088/jcp.24m15438 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Clinical Psychiatry, 2025. Verfasst von Maurizio Fava und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Major Depressive Disorder, Receptors, N-Methyl-D-Aspartate. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Esmethadone is a novel N-methyl-D-aspartate receptor (NMDAR) uncompetitive antagonist in development as adjunctive treatment for major depressive disorder (MDD).

Methods

This 12-month, open-label study evaluated the safety and efficacy of esmethadone in patients with MDD meeting DSM-5 criteria who completed 1 of 3 double-blind studies (rollover) and in patients with MDD and no prior participation in esmethadone studies (de novo). Safety was assessed from adverse events, laboratory parameters, vital signs, electrocardiogram, and the Columbia-Suicide Severity Rating Scale. Efficacy assessments used measures of depression, anxiety, sleep, sexual function, cognitive function, and quality of life. The safety population comprised patients who received at least 1 dose of study drug, and the full analysis set (FAS) comprised patients who had at least 1 postbaseline efficacy assessment.

Results

Safety population included 624 patients; FAS included 586 patients (384 rollover and 202 de novo); mean age was 42.9 (13.6) years, and mean baseline Montgomery-Asberg Depression Rating Scale (MADRS10) was 34.5 (4.8). Most common treatment-related treatment emergent adverse events were headache (4.6%), nausea (4.2%), and dizziness (2.6%). There were no signals of meaningful neurological, cardiovascular, metabolic, or sexual adverse events and no case of suicide or suicidal attempt. For the FAS, mean (SD) change from baseline for MADRS10 at 3, 6, 9, and 12 months was -20.1 (10.7), -21.0 (10.8), -21.6 (10.7), and -21.6 (10.4). For the de novo population, mean (SD) was -19.9 (10.0), -19.9 (10.4), -20.1 (10.2), and -22.5 (9.7). Consistent improvements occurred with other tested efficacy measures.

Conclusions

Long-term treatment with esmethadone was safe and well tolerated. The antidepressant efficacy of esmethadone was sustained over 12 months. Trial Registration: ClinicalTrials.gov identifier: NCT04855760.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderReceptors, N-Methyl-D-AspartateAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodTreatment Outcome

Substanzen

Receptors, N-Methyl-D-Aspartate

Autor:innen und Institutionen

  • Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.
  • Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Miami, Coral Gables, Florida.
  • Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
  • Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York.
  • Neuroscience Education Institute, Carlsbad, California.

Zitieren

APA

Fava, M., Pani, L., De Martin, S., Cutler, A. J., Gorodetzky, C. W., Vocci, F. J., Sapienza, F. L., Kosten, T. R., Kröger, C., Champasa, P., Guidetti, C., Comai, S., Mattarei, A., Folli, F., Bushnell, D., Traversa, S., Inturrisi, C. E., Manfredi, P. L., & Pappagallo, M. (2025). Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.24m15438

Vancouver

Fava M, Pani L, De Martin S, Cutler AJ, Gorodetzky CW, Vocci FJ, et al. Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. 2025. doi:10.4088/jcp.24m15438

BibTeX
@article{Fava2025,
  author = {Fava, Maurizio and Pani, Luca and De Martin, Sara and Cutler, Andrew J and Gorodetzky, Charles W and Vocci, Frank J and Sapienza, Frank L and Kosten, Thomas R and Kröger, Cornelia and Champasa, Paggard and Guidetti, Clotilde and Comai, Stefano and Mattarei, Andrea and Folli, Franco and Bushnell, David and Traversa, Sergio and Inturrisi, Charles E and Manfredi, Paolo L and Pappagallo, Marco},
  title = {Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder},
  journal = {The Journal of Clinical Psychiatry},
  year = {2025},
  doi = {10.4088/jcp.24m15438}
}
Kostenlos starten →